A Phase I,II Open-Label Dose Escalation Study to Evaluate the Safety and Efficacy of Single Doses of TT-034 for Subjects With Chronic Hepatitis C (CHC) Infection
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs TT 034 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; First in man
- Sponsors Tacere Therapeutics
- 28 Nov 2016 Status changed from active, no longer recruiting to completed.
- 03 May 2016 Status changed from recruiting to active, no longer recruiting.
- 25 Apr 2016 Interim results published in the Benitec media release.